Free Trial

Fortrea (FTRE) Competitors

Fortrea logo
$6.23 +0.80 (+14.73%)
As of 12:26 PM Eastern

FTRE vs. GRAL, AHCO, TDOC, VRDN, AVAH, PNTG, CDNA, AGL, FLGT, and LFMD

Should you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include Grail (GRAL), AdaptHealth (AHCO), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), Aveanna Healthcare (AVAH), The Pennant Group (PNTG), CareDx (CDNA), agilon health (AGL), Fulgent Genetics (FLGT), and LifeMD (LFMD). These companies are all part of the "healthcare" industry.

Fortrea vs. Its Competitors

Fortrea (NASDAQ:FTRE) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Fortrea has higher revenue and earnings than Grail. Fortrea is trading at a lower price-to-earnings ratio than Grail, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fortrea$2.69B0.21-$3.40M-$8.79-0.71
Grail$130.71M11.58-$2.19B-$60.99-0.69

In the previous week, Fortrea had 28 more articles in the media than Grail. MarketBeat recorded 49 mentions for Fortrea and 21 mentions for Grail. Grail's average media sentiment score of 0.52 beat Fortrea's score of 0.06 indicating that Grail is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fortrea
1 Very Positive mention(s)
3 Positive mention(s)
39 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Neutral
Grail
5 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Fortrea currently has a consensus target price of $15.00, suggesting a potential upside of 140.77%. Grail has a consensus target price of $31.50, suggesting a potential downside of 25.11%. Given Fortrea's higher probable upside, research analysts clearly believe Fortrea is more favorable than Grail.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea
2 Sell rating(s)
12 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Grail
0 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.25

Fortrea received 9 more outperform votes than Grail when rated by MarketBeat users. However, 33.33% of users gave Grail an outperform vote while only 19.64% of users gave Fortrea an outperform vote.

CompanyUnderperformOutperform
FortreaOutperform Votes
11
19.64%
Underperform Votes
45
80.36%
GrailOutperform Votes
2
33.33%
Underperform Votes
4
66.67%

Grail has a net margin of 0.00% compared to Fortrea's net margin of -10.99%. Fortrea's return on equity of 2.00% beat Grail's return on equity.

Company Net Margins Return on Equity Return on Assets
Fortrea-10.99% 2.00% 0.80%
Grail N/A N/A N/A

Summary

Fortrea beats Grail on 8 of the 15 factors compared between the two stocks.

Get Fortrea News Delivered to You Automatically

Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FTRE vs. The Competition

MetricFortreaMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$563.82M$3.08B$5.60B$8.61B
Dividend YieldN/A31.25%5.28%4.18%
P/E Ratio-1.8213.9327.2219.97
Price / Sales0.21178.25408.95152.58
Price / Cash6.2857.5638.2534.64
Price / Book0.324.757.114.68
Net Income-$3.40M-$22.21M$3.24B$248.05M
7 Day Performance21.68%4.21%2.47%2.40%
1 Month Performance20.04%5.92%8.66%6.14%
1 Year Performance-74.91%14.61%31.22%13.62%

Fortrea Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FTRE
Fortrea
3.2139 of 5 stars
$6.23
+14.7%
$15.00
+140.8%
-78.5%$563.82M$2.69B-1.8218,000Trending News
GRAL
Grail
0.4968 of 5 stars
$37.50
-2.4%
$31.50
-16.0%
N/A$1.35B$130.71M-0.611,360
AHCO
AdaptHealth
3.1337 of 5 stars
$8.75
-2.6%
$13.40
+53.1%
-21.6%$1.21B$3.25B-5.3010,900Positive News
TDOC
Teladoc Health
3.0223 of 5 stars
$6.88
-0.5%
$9.60
+39.4%
-29.0%$1.21B$2.55B-1.195,100
VRDN
Viridian Therapeutics
1.8317 of 5 stars
$13.97
+0.4%
$36.70
+162.7%
+19.5%$1.14B$302K-3.2450Positive News
AVAH
Aveanna Healthcare
1.0357 of 5 stars
$5.47
+2.6%
$5.13
-6.3%
+109.2%$1.07B$2.09B-16.0933,000Positive News
PNTG
The Pennant Group
3.5885 of 5 stars
$28.83
+0.4%
$35.60
+23.5%
+19.2%$993.74M$748.17M42.405,340Analyst Forecast
CDNA
CareDx
3.8148 of 5 stars
$17.08
+0.5%
$30.33
+77.6%
+34.9%$951.03M$346.42M-6.33740Positive News
AGL
agilon health
3.0429 of 5 stars
$2.26
+1.6%
$4.79
+112.2%
-65.9%$933.46M$5.99B-2.40650
FLGT
Fulgent Genetics
3.441 of 5 stars
$20.67
-0.2%
$24.00
+16.1%
+9.6%$629.28M$292.45M-3.741,010
LFMD
LifeMD
1.5592 of 5 stars
$12.85
+5.2%
$11.00
-14.4%
+60.9%$584.01M$234.01M-20.08230Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:FTRE) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners